Thus, our study indicates that loss of adipocyte SERCA2 in obesity/T2D can mediate alterations in adipokine levels, although genetic SERCA2 ablation causes more dramatic effects than those observed in metabolic disease where the reduction in adipocyte SERCA2 is less dramatic (Figure 1E, F, J). This evidence concerns the gene ATP2A2 and Other metabolic disease.